Novel Pharmacotherapies in Parkinson’s Disease

Yousef Tizabi1 · Bruk Getachew1 · Michael Aschner2

Received: 19 March 2021 / Revised: 30 April 2021 / Accepted: 11 May 2021 / Published online: 18 May 2021
© The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature 2021

Abstract
Parkinson’s disease (PD), an age-related progressive neurodegenerative condition, is associated with loss of dopaminergic neurons in the substantia nigra pars compacta (SNpc), which results in motor deficits characterized by the following: akinesia, rigidity, resting tremor, and postural instability, as well as nonmotor symptoms such as emotional changes, particularly depression, cognitive impairment, gastrointestinal, and autonomic dysfunction. The most common treatment for PD is focused on dopamine (DA) replacement (e.g., levodopa = L-Dopa), which unfortunately loses its efficacy over months or years and can induce severe dyskinesia. Hence, more efficacious interventions without such adverse effects are urgently needed. In this review, following a general description of PD, potential novel therapeutic interventions for this devastating disease are examined. Specifically, the focus is on nicotine and nicotinic cholinergic system, as well as butyrate, a short chain fatty acid (SCFA), and fatty acid receptors.

Keywords Parkinsonism · Nicotine · Butyrate · Short-chain fatty acids · Depression · Comorbidity · Combination therapy

Introduction
Parkinson’s disease (PD), the second most common progressive neurodegenerative disorder, is associated with loss of dopaminergic neurons in the substantia nigra pars compacta (SNc) that leads to striatal dopamine (DA) deficiency (Blesa and Przedborski 2014; Hustad and Aasly 2020; Liu 2020; Simon et al. 2020). This loss of dopaminergic neurons results in motor deficits characterized by the following: akinesia, rigidity, resting tremor, and postural instability, as well as nonmotor symptoms that might also involve other neurotransmitter systems including the cholinergic system (Perez 2015; Mirelman et al. 2019; Quik et al. 2019; Stoker and Barker 2020). The nonmotor symptoms may include the following: emotional changes (e.g., depression, apathy and anxiety), cognitive deficits (e.g., mild to severe memory impairment), sleep perturbations (e.g., insomnia/hypersomnia), autonomic dysfunction (e.g., bladder disturbances, orthostatic hypotension, sweating), sensory symptoms (e.g., pain, visual and olfactory deficits), gastrointestinal symptoms (e.g., constipation, nausea), as well as “social symptoms” (e.g., inability to produce facial expression or recognize other’s verbal and nonverbal cues) (Perez 2015; Dinter et al. 2020; Prenger et al. 2020).

Neuronal degeneration in PD involves several cellular and molecular events including accumulation of misfolded proteins, failure of protein clearance, mitochondrial damage, oxidative stress, neuroinflammation, immune dysregulation, apoptosis, excitotoxicity, Ca++ dysregulation, as well as autophagy and dysbiosis (Hurley and Tizabi 2013; Maiti et al. 2017; Reglodi et al. 2017; Zeng et al. 2018; Genovese et al. 2020; Indrieri et al. 2020; Parra et al. 2020; Dorszewska et al. 2021; Giorgi et al. 2021; Harms et al. 2021; Rani and Mondal, 2021). In addition, mutations in a number of genes such as leucine-rich repeat kinase 2 (LRRK2), Parkin RBR E3 ubiquitin protein ligase (PARK2), Parkinson disease protein 7 (PARK7), PTEN-induced putative kinase 1 (PINK1), alpha- synuclein (SNCA), as well as polymorphism in DA receptor D2 gene (DRD2Taq1A) have been identified (Klein and Westenberger 2012; Song et al. 2019; Tran et al. 2020).

Although the etiology remains unsettled, it is believed that PD is a multifactorial disease, with both genetic and environmental factors playing a role. The biggest risk factor for PD is old age, where median age of onset is estimated to
be around 60 years of age (Lees et al. 2009; Kouli et al. 2018). In addition, it is postulated that exposure to environmental toxicants such as pesticides, herbicides, and heavy metals may increase the risk of PD (Anderson et al. 2020; McKnight and Hack 2020). In the early 1980s, it was discovered that injection of underground laboratory preparations of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) could result in nigrostriatal degeneration and development of typical PD motor symptoms. MPTP is a potent analog of the opioid analgesic meperidine that gets metabolized into the neurotoxin MPP+(1-methyl-4-phenylpyridinium). MPP+ is a mitochondrial complex-I inhibitor as well as substrate for DA transporter (DAT) and has been shown to selectively damage the dopaminergic cells in SNpc (Langston et al. 1983; Fujita et al. 2020). For this reason, MPTP models of PD are commonly used to investigate the mechanism of neurotoxicity and/or development of novel therapeutics (Schneider et al. 2021; Zheng et al. 2021). Similarly, rotenone, a pesticide which is also selective inhibitor of mitochondrial complex-I, is used in animal models of PD (Betarbet et al. 2000; Kouli et al. 2018). In addition, exposure to heavy metals such as manganese (Peres et al. 2016; Andrade et al. 2017; Ilevra et al. 2020) or iron (Ganz, 2018; Huang et al. 2019; Ndayisaba et al. 2019; Shi et al. 2019) have also been implicated in PD etiology. Interestingly, reduction of iron content via clioquinol was associated with a remarkable improvement of the motor and nonmotor deficits in an MPTP-induced monkey model of PD (Shi et al. 2020).

The most common treatment of PD is focused on DA replacement (e.g., levodopa=L-Dopa), which unfortunately losses its full efficacy in few years and can induce severe dyskinesia, or abnormal involuntary movements (Quik et al. 2019; Sy and Fernandez 2020; Bjørklund et al. 2020). For this reason, DA receptor agonists such as pramipexole and ropinirole may be used initially and inhibitors of DA metabolizing enzymes such as selegiline or rasagiline, both monoamine oxidase (MOA) inhibitors, or catechol-O-methyltransferase (COMT) inhibitors such as entacapone and tolcapone are often used in combination with L-Dopa (Aradi and Hauser 2020; Zheng et al. 2021). Nonpharmacologic interventions including repetitive transcranial magnetic stimulation (rTMS), and in specific circumstances neurosurgery (i.e., deep brain stimulation) may also be applied (Li et al. 2020a; Sui et al. 2021). In addition, significant efforts are devoted to development of autologous, stem cell-derived grafts, as well as viral gene therapies (Stoker et al. 2018; Osborn et al. 2020; Stoker and Barker 2020; Tao et al. 2021). Nonetheless, more efficacious interventions targeting the neurodegenerative aspect of the disease are urgently needed. Here, we discuss potential use of nicotine or nicotinic cholinergic agonists/modulators alone or together with butyrate, a short-chain fatty acid and fatty acid 3 receptor (FA3R) agonists as alternative and/or additional interventions in PD treatment (Fig. 1).

**nAChRs**

The inverse relationship between PD incidence and any form of nicotine intake such as cigarette smoking (Hernán et al. 2002; Ritz et al. 2007; Li et al. 2015), smokeless tobacco (O’Reilly et al. 2005; Liu et al. 2017b; Yang et al. 2017), exposure to environmental tobacco smoke (Searles Nielsen et al. 2012; Han et al. 2019a; Liu et al. 2020), or even from a dietary source such as peppers (Ma et al. 2020) suggests a therapeutic potential for nicotine in PD. This contention is further supported by numerous preclinical studies indicating neuroprotective effects of nicotine, especially in dopaminergic cell models as well as in vivo models of PD (discussed below). Hereby, following a brief discussion of nicotinic cholinergic system, we will focus on its therapeutic utility in PD.

Nicotine’s main targets are nicotinic receptors (nAChRs) that are widely distributed in the central nervous system (Clark and Pert 1985; Dani 2015; Wills and Kenny 2021). nAChRs belong to ionotropic class of receptors, which act by regulating directly the opening of a cation channel in

---

**Fig. 1** Schematic diagram depicting current pharmacotherapies for PD which result in symptomatic relief of symptoms due increase in the striatal DA (left panel). Potential novel intervention that may target the neurodegenerative aspect of the disease and may also help with nonmotor symptoms (right panel).
the neuronal membrane (Dani 2015; Changeux 2018; Papke and Lindstrom 2020). Various subtypes of these receptors
with distinct anatomical, physiological, and pharmacological
characteristics have been identified (Dani 2015). Although nAChRs are present at various sites and in various organs
such as neuromuscular junction, autonomic ganglia, and the
central nervous system, the subunit structures of these recep-
tors are different from each other (Kalamida et al. 2007).
Considerable information on interaction between neuronal
nAChRs consisting mainly of alph4-beta2 or homomeric
alpha7 subunits and other neurotransmitter systems is now
available (Wittenberg et al. 2020; Wills and Kenny 2021).
Moreover, specific responses of these receptors to nicotine
and their involvement in cognitive functions have been
investigated (Valentine and Sofuoglu 2018; Azimi et al.
2020). Indeed, a potential role of nAChRs in high-order
cognitive processing has been suggested (Koukouli and
Changeux 2020). Therapeutic potential for selective nAChR
agonists in various neuropsychiatric and neurodegenerative
disorders including PD (Quik et al. 2019; Tizabi et al. 2019;
Liu 2020), depression (Gandelman et al. 2018; Tizabi et al.
2019; Conti et al. 2020), mild cognitive impairment or Alz-
heimer’s disease (Vega et al. 2019; Azimi et al. 2020; Hahn
et al. 2020; Koukouli and Changeux 2020), ischemia (Han
et al. 2020b), schizophrenia (Terry and Callahan, 2020), pain
(Bagdas et al. 2018), as well as energy balance (Seoane-
Collazo et al. 2021) have been proposed. Given that there
is a relatively high comorbid existence between depression
and PD, a nicotinic intervention may have the added advan-
tage of addressing both issues at the same time (Tizabi et al.
2019).

Role of the Nicotinic Cholinergic System
in Parkinson’s Disease

Multiple studies indicate that the normal function of the
basal ganglia, intimately involved in movement regulation,
is dependent on the equilibrium between the midbrain
dopaminergic and striatal cholinergic systems (Aosaki
et al. 2010; Scarduzio et al. 2017; Assous, 2021). Thus,
aeetylcholine can regulate striatal DA release via an
interaction at various nAChRs (Quik et al. 2019; Liu 2020).
Further importance of ACh in the basal ganglia is evident
from the effect of cholinergic agents in patients suffering
from various neurological disorders such as Tourette
syndrome, dystonia, as well as PD (Assous, 2021). In
various experimental animal models of PD (e.g., 6-OHDA
lesioned rodents), the impairments in DA release appear to
be exacerbated by loss of nAChRs activation, suggesting that
nicotinic agonists may ameliorate the dopaminergic imbalance
and may thus be useful therapeutic targets for PD (Shimohama
and Kawamata, 2018; Quik et al. 2019). In this regard, a
number of in vitro and in vivo studies including primates
and genetically modified mice have shown protective effects
of nicotine against neuronal damage and/or neurotoxicity
induced by 6-OHDA, MPTP, rotenone, methamphetamine,
glutamate, and β-amyloid (reviewed in: Shimohama and
Kawamata, 2018; Quik et al. 2019; Tizabi et al. 2019). These
effects are mediated via selective nAChR subtypes containing
β2 and α7 subunits (see Quik et al. 2019; Tizabi et al. 2019).
We have also observed protective effects of nicotine against
dogenous substances such as salsolinol (discussed later)
and aminochrome that selectively damage dopaminergic cells
(see Tizabi et al. 2019). More recently, protective effects of
nicotine against toxicity induced by iron and manganese
were also observed in cell culture (Getachew et al. 2019a).
Additionally, Quik et al. (2019) have shown beneficial effects
of nicotine against L-Dopa-induced dyskinesia in nonhuman
primate models. Interestingly, nicotinic cholinergic system
may also play a role in L-Dopa-induced dyskinesias (Bordia
and Perez 2019). Hence, targeting nicotinic cholinergic
receptors appears to offer a novel intervention in PD (Tizabi
and Getachew, 2017, Quick, 2019; Tizabi et al. 2019, Liu
2020; Vetel et al., 2021). Nicotine’s effects are likely to
involve suppression of pro-inflammatory cytokines and
stimulation of neurotrophic factors as well as suppression of
oxidative stress (Barreto et al. 2015; Perez 2015; Tizabi 2019;
Dong et al. 2020; Vetel et al. 2021).

Several human studies have assessed the effects of nico-
tine gum or patch in PD, most of which have not yielded
positive results (Vieregge et al. 2001; Lemay et al. 2004;
see also Tizabi and Getachew 2017). The negative finding
in these trials is likely due to the mode of administration
of nicotine (Tizabi and Getachew 2017). Thus, it is very
important to consider the route of nicotine administration,
where subdermal administration via patch may not achieve
the desirable nicotinic receptor stimulation obtained via
pulsatile nicotine (e.g., via inhalation) (Feathersone and
Siegel 2015; Tizabi and Getachew 2017). The very com-
plex dynamic interaction of nicotine with its receptors,
where initial stimulation can be followed by rapid and dif-
ferential desensitization of receptor subtypes, has to be
considered critically in experimental paradigms so that
maximal therapeutic outcome may be obtained (Dani 2015;
Tizabi and Getachew 2017; Quik et al. 2019). Thus, it may
be suggested that pulsatile stimulation of specific nAChRs
in selective brain regions, particularly in the nigrostriatal
pathway would be critical for its therapeutic effects in PD.
This could be achieved by administering nicotine via inha-
lation, or nasal spray. It is of relevance to note that a recent
clinical study using oral administration of nicotine, reported
positive effects of nicotine on falls and freezing gait in PD
(Lieberman et al. 2019). Furthermore, pulsatile nicotine
preparations in forms of inhalers or nasal spray are avail-
able and approved by FDA for smoking cessation and could
be re-purposed for PD pending evaluation of their effectiveness in clinical trials. In addition, as alluded to earlier, potential usefulness of a pulsatile nicotine administration in improving nonmotor symptoms (e.g., depression or cognitive decline) that are commonly associated with PD (Quik et al. 2015; Tizabi and Getachew 2017; Tizabi et al. 2019), could be an added advantage of nicotinic therapy (Fig. 1).

Still, the addictive properties of nicotine (Stolerman and Jarvis, 1995; Willis and Kenny, 2021) might be of concern in its therapeutic application. In this regard, significant efforts are expanded in developing selective nicotinic receptor subtype agonists or nicotinic receptor modulators that would be of similar potency but without the addictive component (Ryan et al., 2001; Bordia et al., 2015). Nonetheless, taking into account the risk/benefit ratio of nicotine, it might still be a useful tool in PD until more suitable nonaddictive compounds are developed (Mitra et al. 2020).

It is of utmost importance, however, to emphasize that the suggested interventions are for pure nicotine available via pharmaceutical preparation and not smoking. The detrimental consequences of tobacco (chewed or smoked) or even e-cigarettes on various organs and lately in COVID-19 pandemic have been recognized (Li et al. 2020b; Ruszkiewicz et al. 2020; Tizabi et al. 2020), and hence, none of such modes should be attempted as self-medication by any PD patient. Moreover, controlled clinical trials of nicotinic preparations to establish the dose and efficacy and ultimate FDA approval are required for any nicotinic intervention in PD.

**Butyrate**

Butyrate is a short-chain fatty acid (SCFA) that is produced by gut microbiota and acts primarily as an energy source for colonic epithelial cells and has been shown to have anti-inflammatory, enteroendocrine and epigenetic effects that not only influences colonic and systemic health but can also affect the brain function (Cantu-Jungles et al., 2019). Recent advances in our understanding of the gut-brain axis has resulted in new insights and potential novel targets for therapeutic intervention in PD (Baizabal-Carvallo and Alonso-Juarez, 2020; Cirstea et al. 2020; Cryan et al. 2020). Indeed, it has been suggested that the initiation and progression of PD may be impeded through manipulation of the gut microbiota. Specifically, it has been suggested that misfolding of alpha-synuclein (α-Syn), a protein highly implicated in PD pathology, can be brought about via dysbiosis or altered colonic microbiota and subsequent neuroinflammation (Keshavarzian et al. 2015; Sampson et al. 2016; Meng et al. 2019; Koutzoumis et al. 2020). This contention is further supported by the observation that the composition of the gut microbiota and SCFAs might be altered in patients with PD (Unger et al. 2016; Nuzum et al. 2020; Shin et al. 2020). Thus, there is a strong indication for therapeutic use of SCFAs, particularly butyrate, the most studied SCFA, for PD treatment. In this regard, a few studies have shown beneficial effects of sodium butyrate in various animal models of PD (St Laurent et al. 2013; Liu et al. 2017a; Funakohi-Tago et al. 2018; Russo et al. 2018; Srivastav et al. 2019; Hou et al. 2021), although at higher doses, this compound might aggravate the colonic inflammation in an MPTP mouse model (Qiao et al. 2020a). In vitro and in vivo studies have consistently found protective effects of sodium butyrate against dopaminergic cell damage brought about by alpha-synuclein (Paiva et al. 2017; Qiao et al. 2020b). This protection is against both transcriptional deregulation and DNA damage (Paiva et al. 2017). The postulated mechanism for in vivo effect of sodium butyrate in degradation of α-synuclein is via Atg5-dependent and PI3K/Akt/mTOR-related autophagy pathway (Qiao et al. 2020b). Beneficial effects of butyrate in PD are further evidenced by its attenuation of neurotoxic or motor impairments induced by 6-hydroxydopamine, roteneone, and MPTP (Funakohi-Tago et al. 2018; Srivastav et al. 2019; Hou et al. 2021).

We have also observed that butyrate as well as AR 420,626 (AR), chemical name: N-(2,5-dichlorophenyl)-4-[(furan-2-yl)-2-methyl-5-oxo-1,4,5,6,7,8-hexahydroquinoline-3-carboxamide), another agonist of the fatty acid-3 receptor (FA3R), can protect against salsolinol-induced toxicity in SH-SY5Y cells, which as discussed below has important implications for PD (Getachew et al. 2020). Salsolinol (SALS = 1-methyl-6,7-dihydroxy-1,2,3,4-tetrahydroisoquino-line), which has structural similarity with MPTP, is an adduct formed as a condensation product of DA and aldehydes and is considered an endogenous DA modulator with selective toxicity to dopaminergic neurons in the substantia nigra (Storch et al. 2002; Maruyama et al. 2004; Naoi et al. 2004; Mrevac 2006). Dysregulation of SALS, especially its (R) enantiomer in the brain, is thought to contribute to development of PD (Antkiewicz-Michaluk 2002; Xicoy et al. 2017). The observed higher level of SALS in the cerebrospinal fluid and urine of PD patients has led to the suggestion of its measurement as a potential marker for PD (Storch et al. 2002; Maruyama et al. 2004; Naoi et al. 2004; Sharma et al. 2013; Zheng et al. 2018; Voon et al. 2020), although elevated levels of systemic derivatives of norsalsolinol may also arise from the metabolism of levodopa (Scholz et al. 2004). That SALS may actually be produced by gut microbiota, further strengthens the gut-brain axis hypothesis of PD (Villalgolín et al. 2018). SH-SY5Y cells, human neuroblastoma-derived cell line, express high levels of dopaminergic activity and are used extensively to study possible mechanism(s) of toxicity and protection in nigral dopaminergic neurons (Copeland et al. 2007; Qualls et al. 2014; Xicoy et al. 2017; Getachew et al. 2019a). As alluded to above, we observed that both butyrate
and AR, a FA3 receptor agonist (Hudson et al. 2014; Bolognini et al. 2016; Kaji et al. 2018), fully blocked SALS-induced toxicity. However, the effect of butyrate was blocked partially, whereas the effect of AR was blocked totally by beta-hydroxy butyrate (BHB), a selective FA3R antagonist. This suggests that some of the effects of butyrate might be independent of FA3R activation (see below). However, since at least part of the butyrate effect is mediated through FA3R stimulation, it would not be unreasonable to suggest that agonists of this receptor might also be of therapeutic potential in PD treatment (Getachew et al. 2020) (Fig. 1).

Several mechanisms of action, including histone deacetylase (HDAC) inhibition, activation of Nrf2/HO-1 axis (activation of antioxidant defense and detoxifying genes), stimulation of glucagon like peptide-1, as well as binding to several specific G protein–coupled receptors (GPCRs) such as FA2R and FA3R (Liu et al. 2017a; Funakohi-Tago et al. 2018; Cantu-Jungles et al. 2019) have been attributed to butyrate. That the effect of butyrate was partially blocked by a specific FA3R antagonist suggests that mechanism(s) other than activation of FA3R are also involved in its neuroprotective effects (Getachew et al. 2020). In this regard, protective effects of sodium butyrate against dopaminergic cell damage in vitro has been attributed mainly to HDAC inhibition (Paiva et al. 2017). Hence, targeting HDAC may also be a viable source for novel intervention in PD (Fig. 1).

It is noteworthy that butyrate not only may have neuroprotective effects but may also have beneficial application against several other diseases including graft rejection, inflammatory bowel disease, colorectal cancer, and diabetes, all of which carry an inflammatory component (Tikhonova, 2017; Alrafas et al. 2019; Baxter et al. 2019). More recently, butyrate was also advocated for treatment of obesity and sleep disorders (Baxter et al. 2019; Szentirmai et al. 2019). However, a possible drawback to butyrate’s therapeutic use may be its poor pharmacological properties including short half-life and first-pass hepatic clearance (Witt et al. 2003; Sampathkumar et al. 2006; Yoo and Jones 2006; Ghosh et al. 2012). Therefore, if AR or any other selective FA3R agonist, with a better pharmacologic profile than butyrate, show similar effects as butyrate, then their use in the myriad of diseases mentioned above can be advocated. Moreover, since some of protective effects of butyrate may be due to HDAC inhibition, it would be of importance to determine whether such compounds would also have a similar effect on HDAC (Srivastav et al. 2019). Nonetheless, it is noteworthy that several selective FA3R agonists including AR were shown to be effective in blocking NSAID-induced enteropathy (intestinal pathology) in rats (Said et al. 2017).

Similar to what was observed for nicotine, butyrate also has shown antidepressant properties. Thus, it was observed that sodium butyrate functions as an antidepressant in several animal models of depression including maternal deprivation and chronic mild stress (Gundersen and Blendy 2009; Valvassori et al. 2014). More recently, it was reported that sodium butyrate also ameliorates depressive-like behavior in lipopolysaccharide-induced depression and that this effect is mediated via inhibition of neuroinflammation and oxido-nitrosative stress (Qiu et al. 2020). These effects are likely mediated through FA3R stimulation as it was shown that histone deacetylation inhibition was not a mechanism for butyrate’s antidepressant effect (Gundersen and Blendy 2009).

As mentioned previously, there is relatively high comorbid existence between depression and PD. Hence, here also intervention by butyrate may have the added advantage of addressing both issues at the same time (Tizabi et al. 2019). In this regard, it is also noteworthy that drugs that have neuroprotective effects are likely to also show mood regulating and antidepressant properties (Tizabi 2016). On the other hand, antidepressants are also likely to show at least some neuroprotective effects (Tizabi 2016). This duality of neuroprotective/antidepressant effects are likely due to some overlap of circuitries as well as common neurobiological substrates involved in dysregulation of mood and neurodegenerative phenotypes, particularly in PD (Tizabi 2016; Tizabi et al. 2019). Moreover, recent advances also strongly connect gut microbiota not only with neurodegenerative diseases as discussed above but also with pain (Russo et al., 2018), neurodevelopmental disorders such as autism (Almeida et al. 2020; Lungba et al. 2020; O’Connor et al. 2021), neuropsychiatric disorders such as schizophrenia (Dinan and Cryan 2020; Kelly et al. 2020), and particularly depression (Caspani et al. 2019; Cruz-Pereira and Cryan, 2020). Several mechanisms including deficits in neurogenesis and synaptogenesis, reduced cortical and hippocampal expression of brain-derived neurotrophic factor (BDNF), exaggerated hypothalamic pituitary adrenal (HPA) axis response, and neuroinflammation have been implicated in dysbiosis and depressive-like characteristics (Caspani et al. 2019; Getachew et al. 2019b; Getachew and Tizabi 2019; Cruz-Pereira and Cryan 2020). Since as mentioned earlier, depression is a common manifestation with PD, agents such as butyrate or other compounds interacting with gut microbiota would be ideal candidates for further investigation in comorbid conditions.

**Combination Therapy**

An important consideration in disease modification is potential combination of drugs with various mechanism of action to affect the chain of events at various sites to prevent the pathology and/or the phenotype. Thus, it might prove prudent to combine the aforementioned drugs, namely nicotine and/or nicotinic agonists/
modulators with butyrate and/or an FA3R agonist for maximum efficacy. Moreover, such drugs may be added to current medications used in PD to improve therapeutic outcome, particularly for comorbid conditions. In this regard, some of the current medications might actually be targeting some of the same sites discussed above, albeit to a lesser degree. For example, it was recently demonstrated that COMT inhibitors that are commonly used in PD can also affect the gut microbiota implicated in PD (Grün et al. 2020). Interestingly, recent studies also provide evidence of nicotine interaction with gut microbiota (Chi et al. 2017; Pavia and Plummer 2020). Specifically, it was demonstrated that oxidative stress response as well as DNA repair genes were particularly enriched in gut microbiome of mice treated with nicotine (Chi et al. 2017). Thus, multi-level effects of nicotine and butyrate would render their potential additive or synergistic effects in PD and perhaps more specifically in PD-depression comorbidity a very viable outcome. In support of this contention, we have recently observed a synergistic interaction between nicotine and butyrate against SALS-induced toxicity in SH-SY5Y cells (under preparation).

In summary, nicotine or nicotinic agonists or modulators alone or together with butyrate and/or FA3R agonists hold significant promise as novel therapeutic interventions in PD.

Funding Supported by NIH/NIAAA R03AA022479 and Howard University College of Medicine Bridge Funds and Pilot Study Awards Program (BFP SAP) 2020–2021 (YT) and NIH/NIEHS R01ES10563 and R01ES07331 (MA).

Declarations

Conflict of Interest The authors declare no competing interests.

References

Almeida C, Oliveira R, Soares R, Barata P (2020) Influence of gut microbiota dysbiosis on brain function: a systematic review. Port Biomed j 5(2):1–8
Alrphas HR, Busbee PB, Nagarkatti M (2019) Nagarkatti PS Resveratrol modulates the gut microbiota to prevent murine colitis development through induction of Tregs and suppression of Th17 cells. J Leukoc Biol 106(2):467–480
Anderson CC, Marenette JO, Rauniyar AK, Prutton K, Khatri M, Matheson C et al (2020) Maneb alters central carbon metabolism and thiol redox status in a toxicant model of Parkinson’s disease. Free Radic Biol Med S0891-5849(20):31641–31645
Andrade VM, Aschner M (2017) Marreilha Dos Santos AP. Neurotoxicity of Metal Mixtures Adv Neurobiol 18:227–265
Antkiewicz-Michaluk L (2002) Endogenous risk factors in Parkinson’s disease: dopamine and tetrahydroisoquinolines. Pol J Pharmacol 54:567–572
Aosaki T, Miura M, Suzuki T, Nishimura K, Masuda M (2010) Acetylcholine-dopamine balance hypothesis in the striatum: an update. Geriatr Gerontol Int 10(Suppl 1):S148–S157
Aradi SD, Hauser RA (2020) Medical management and prevention of motor complications in Parkinson’s disease. Neurotherapeutics 17(4):1339–1365
Assous M (2021) Striatal cholinergic transmission. Focus on nicotinic receptors’ influence in striatal circuits. Eur J Neurosci. 53(8):2421–2442
Azimi M, Oemisch M, Womelsdorf T (2020) Dissociation of nicotinic α7 and α4/β2 sub-receptor agonists for enhancing learning and attentional filtering in nonhuman primates. Psychopharmacology 237(4):997–1010
Bagdas D, Gurun MS, Flood P, Papke RL, Damaj MI (2018) New insights on neuronal nicotinic acetylcholine receptors as targets for pain and inflammation: a focus on α7 nAChRs. Curr Neuropsychopharmacol 16:415–425
Baizabal-Carvallo JF, Alonso-Juarez M (2020) The link between gut dysbiosis and neuroinflammation in Parkinson’s disease. Neuroscience 432:160–173
Barreto GE, Iarkov A, Moran VE (2015) Beneficial effects of nicotine, cotinine and its metabolites as potential agents for Parkinson’s disease. Front Aging Neurosci 6:340
Baxter NT, Schmidt AW, Venkataraman A, Kim KS, Waldron C, Schmidt TM (2019) Dynamics of human gut microbiota and short-chain fatty acids in response to dietary interventions with three fermentable fibers. mBio. 10(1):e02566–18
Betarbet R, Sherer TB, MacKenzie G, Garcia-Osuna M, Panov AV, Greenamyre JT (2000) Chronic systemic pesticide exposure reproduces features of Parkinson’s disease. Nat Neurosci 3(12):1301–1306
Björklund G, Dadar M, Anderson G, Chirumbolo S, Maes M (2020) Preventive treatments to slow substantia nigra damage and Parkinson’s disease progression: a critical perspective. Review Pharmacol Res 161:105065
Blesa J, Przedborski S (2014) Parkinson’s disease: animal models and dopaminergic cell vulnerability. Front Neuroanat 8:155
Bolognini D, Tobin AB, Milligan G, Moss CE (2016) The pharmacology and function of receptors for short-chain fatty acids. Mol Pharmacol 89(3):388–398
Bordia T, McGregor M, Papke RL, Decker MW, McIntosh JM, Quik M (2015) The α7 nicotinic receptor agonist ABT-107 protects against nigrostriatal damage in rats with unilateral 6-hydroxydopamine lesions. Exp Neurol 263:277–284
Bordia T, Perez XA (2019) Cholinergic control of striatal neurons to modulate L-dopa-induced dyskinesias. Eur J Neurosci 49(6):859–868
Cantu-Jungles TM, Rasmussen HE, Hamaker BR (2019) Potential of prebiotic butyrogenic fibers in Parkinson’s disease. Front Pharmacol 10:663
Caspani G, Kennedy S, Foster JA, Swann J (2019) Gut microbiotal interactions in depression: understanding the biochemical mechanisms. Microb Cell 6(10):454–481
Changeux JP (2018) The nicotinic acetylcholine receptor: a typical “allosteric machine.” Philos Trans R Soc Lond B Biol Sci 373(1749):20170174
Chi L, Mahbub R, Gao B, Bian X, Tu P, Ru H et al (2017) Nicotine alters the gut microbiome and metabolites of gut-brain interactions in a sex-specific manner. Chem Res Toxicol 30(12):2110–2119
Cirstea MS, Yu AC, Golz E, Sundvick K, Kliger D, Radisavljevic N et al (2020) Microbiota composition and metabolism are associated with gut function in Parkinson’s disease. Mov Disord 35(7):1208–1217
Clarke PB, Pert A (1985) Autoradiographic evidence for nicotine receptors on nigrostriatal and mesolimbic dopaminergic neurons. Brain Res 348(2):355–358

Springer
Tizabi Y, Getachew B (2017) Nicotinic receptor intervention in Parkinson’s disease: future directions. Cin Pharm Transl Med 1:1–7
Tizabi Y, Getachew B, Csoka AB, Manaye KF, Copeland RL (2019) Novel targets for parkinsonism-depression comorbidity. Prog Mol Biol Transl Sci 167:1–24
Tizabi Y, Getachew B, Copeland RL, Aschner M (2020) Nicotine and the nicotinic cholinergic system in COVID-19. FEBS j 287(17):3656–3663
Tran J, Anastacio H, Bardy C (2020) Genetic predispositions of Parkinson’s disease revealed in patient-derived brain cells. npj Parkinsons Dis. 6:8
Unger MM, Spiegel J, Unger MM, Spiegel J, Dillmann KU, Grundmann D et al (2016) Short chain fatty acids and gut microbiota differ between patients with Parkinson’s disease and age-matched controls. Parkinsonism Relat Disord 32:66–72
Valentine G, Sofuoglu M (2018) Cognitive effects of nicotine: recent progress. Curr Neuropharmacol 16(4):403–414
Valvasori SS, Varela RB, Arent CO, Dal-Pont GC, Bobsin TS, Budni J et al (2014) Sodium butyrate functions as an antidepressant and improves cognition with enhanced neurotrophic expression in models of maternal deprivation and chronic mild stress. Curr Neurovasc Res 11(4):359–366
Vega JN, Albert KM, Mayer IA, Taylor WD, Newhouse PA (2019) Nicotinic treatment of post-chemotherapy subjective cognitive impairment: a pilot study. J Cancer Surviv 13(5):673–686
Vetel S, Foucault-Fruchard L, Bronc F, Vergote J, Bodard S et al (2021) Neuroprotective and anti-inflammatory effects of a therapy combining agonists of nicotinic α7 and σ1 receptors in a rat model of Parkinson’s disease. Neural Regen Res 16:1099–1104
Vieregge A, Sieberer M, Jacobs H, Hagenah JM, Vieregge P (2001) Transdermal nicotine in PD: a randomized, double-blind, placebo-controlled study. Neurol 57:1032–1035
Villageliú DN, Borts DJ, Lyte M (2018) Production of the neurotoxin salsolinol by a gut-associated bacterium and its modulation by alcohol. Front Microbiol 9:3092
Voon SM, Ng KY, Chye SM, Ling APK, Voon KGL, Yap YJ et al (2020) The mechanism of action of salsolinol in brain: implications in Parkinson’s disease. CNS Neurol Disord Drug Targets 19(10):725–740
Wills L, Kenny PJ (2021) Addiction-related neuroadaptations following chronic nicotine exposure. J Neurochem. https://doi.org/10.1111/jnc.15356. Epub ahead of print. PMID: 33742685
Witt O, Monkeleyer S, Röndahl G, Erdlenbruch B, Reinhardt D, Kanbach K et al (2003) Induction of fetal hemoglobin expression by the histone deacetylase inhibitor apicidin. Blood 101(5):2001–2007
Wittenberg RE, Wolfman SL, De Biasi M, Dani JA (2020) Nicotinic acetylcholine receptors and nicotine addiction: a brief introduction. Neuropharmacology 177:108256
Xicoy H, Wieringa B, Martens GI (2017) The SH-SY5Y cell line in Parkinson’s disease research: a systematic review. Mol Neurodegener 12(1):10
Yang F, Pedersen NL, Ye W, Liu Z, Norberg M, Forsgren L et al (2017) Moist smokeless tobacco (Snus) use and risk of Parkinson’s disease. Int J Epidemiol 46:872–880
Yoo CB, Jones PA (2006) Epigenetic therapy of cancer: past, present and future. Nat Rev Drug Discov 5(1):37–50
Zeng XS, Geng WS, Jia JJ, Chen L, Zhang PP (2018) Cellular and molecular basis of neurodegeneration in Parkinson disease. Front Aging Neurosci 10:109
Zheng X, Chen X, Guo M, Ali S, Huang Y, Sun F et al (2018) Changes in salsolinol production and salsolinol synthase activity in Parkinson’s disease model. Neurosci Lett 673:39–43
Zheng M, Chen M, Liu C, Fan Y, Shi D (2021) Alkaloids extracted from Uncaria rhynchophylla demonstrate neuroprotective effects in MPTP-induced experimental parkinsonism by regulating the PI3K/Akt/mTOR signaling pathway. J Ethnopharmacol 266:113451

Publisher’s Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.